| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.3 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.3 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.3 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.058 | 0.3 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.068 | 0.3 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |